8 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseAlzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 32026-10-06NCT06976216
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionDepressive Disorder, Treatment-Resistant, depressive disorder, mood disorder, psychiatric disorderRecruitingPhase 32026-09-25NCT07716098
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptomsdepressive disorder, major depressive disorder, mood disorder, psychiatric disorderRecruitingPhase 32026-09-25NCT06559306
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorderanxiety disorder, generalized anxiety disorder, psychiatric disorderRecruitingPhase 22026-09-25NCT06480383
A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorderanxiety disorder, generalized anxiety disorder, psychiatric disorderRecruitingPhase 32026-09-10NCT07767903
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyActive, not recruitingPhase 32026-08-26NCT04437511
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorderdepressive disorder, major depressive disorder, mood disorder, psychiatric disorderRecruitingPhase 22026-07-27NCT07115329
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyActive, not recruitingPhase 32026-01-21NCT05026866